Related Experiment Video

Updated: Dec 17, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Bendamustine Monotherapy for Primary Cutaneous Gamma-Delta T-Cell Lymphoma

Alexander Kreuter1, Bijan Koushk-Jalali1, Georgios Mitrakos1

  • 1Department of Dermatology, Venereology, and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Oberhausen, Germany.

JAMA Dermatology
|June 26, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.4K

Related Experiment Videos

Last Updated: Dec 17, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

Articles linked to this work by shared authors, journal, and citation graph.

Lichen sclerosus. Part 2. Guideline of the DGG, DGGG, OEGGG and SGGG (S3-Level, AWMF Registry No. 013-105, July 2025.

Geburtshilfe und Frauenheilkunde·2026

Lichen sclerosus. Part 1. Guideline of the DGG, DGGG, OEGGG and SGGG (S3-Level, AWMF Registry No. 013-105, July 2025.

Geburtshilfe und Frauenheilkunde·2026

[Gemcitabine-induced toxic epidermal necrolysis in a patient with mycosis fungoides].

Dermatologie (Heidelberg, Germany)·2026

Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for SSc cohort.

Arthritis research & therapy·2026

Topical trichloroacetic acid versus electrocautery for treatment of anal intraepithelial neoplasia in people living with HIV: a multicentre, randomised, non-inferiority trial (TECAIN-study).

Infection·2026

Prurigo Pigmentosa - an increasingly diagnosed dermatological condition associated with ketogenic diet.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant.

JAMA dermatology·2026

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

JAMA dermatology·2026

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa.

JAMA dermatology·2026

Pyoderma Gangrenosum Phenotype Classification.

JAMA dermatology·2026

Enfortumab Vedotin-Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma.

JAMA dermatology·2026

Early Respiratory Infection Burden and Atopic Dermatitis in Childhood.

JAMA dermatology·2026

Intraoperative Imprint Cytology Versus Frozen Section for Sentinel Lymph Node Assessment in Breast Carcinoma: A Prospective Diagnostic Accuracy Study From a Resource-Limited Setting in Eastern India.

Cureus·2026

ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?

Annals of surgical oncology·2026

[Analysis of clinicopathological and immunological characteristics of patients with acquired immune deficiency syndrome-associated diffuse large B-cell lymphoma complicated by Talaromyces marneffei infection].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026

Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes:A Large Cohort Study.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

The Lancet. Haematology·2026

Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us